Use of sulforaphane in COVID-19: Clinical trials are needed

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan

Research output: Contribution to journalLetterpeer-review

Abstract

We read with interest the narrative review authored by Kiser et al. (2021), which discussed extensively the antioxidant effect and anti-inflammatory effect of sulforaphane, a dietary supplement found in high amounts in cruciferous vegetables that is orally accessible and well-tolerated. Notably, in their review, the authors also discussed the potential use of sulforaphane in patients with coronavirus disease 2019 (COVID-19). Sulforaphane mediates the inhibitory effect on NLRP3 inflammasome activation and we believe that this could be the main mechanism where sulforaphane is useful for patients with COVID-19.

Original languageEnglish
Pages (from-to)78-79
Number of pages2
JournalMolecular Immunology
Volume145
Early online date15 Mar 2022
DOIs
Publication statusPublished - 1 May 2022

Fingerprint

Dive into the research topics of 'Use of sulforaphane in COVID-19: Clinical trials are needed'. Together they form a unique fingerprint.

Cite this